Largest pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 pharmaceutical companies ranked by revenue, at CHF 79.4B, ahead of Eli Lilly (CHF 54.9B) and Merck & Co (CHF 54.8B). Figures as of 18 Nov 2026, 17:48 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonCHF 79.4B
- Median
- CHF 2.7B
- Combined market value
- CHF 4.29T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | CHF 79.4B | CHF 560.3B | CHF 232.74 | 0.93% down | 38% up | ||
| 2 | Eli LillyLLY · Health Care | CHF 54.9B | CHF 1.04T | CHF 1,171.44 | 1.82% down | 35% up | ||
| 3 | Merck & CoMRK · Health Care | CHF 54.8B | CHF 288.4B | CHF 117.00 | 3.19% down | 51% up | ||
| 4 | PfizerPFE · Health Care | CHF 52.7B | CHF 135.3B | CHF 23.74 | 1.07% down | 14% up | ||
| 5 | AbbVieABBV · Health Care | CHF 51.6B | CHF 428.8B | CHF 242.60 | 1.71% down | 26% up | ||
| 6 | AstraZenecaAZN · Health Care | CHF 49.5B | CHF 234.6B | CHF 151.24 | 1.56% down | 2% up | ||
| 7 | NovartisNVS · Health Care | CHF 46B | CHF 248.3B | CHF 131.48 | 1.98% down | 25% up | ||
| 8 | SanofiSNY · Health Care | CHF 40.8B | CHF 95.7B | CHF 39.87 | 0.47% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | CHF 40.6B | CHF 103.4B | CHF 50.59 | 2.18% down | 34% up | ||
| 10 | Novo NordiskNVO · Health Care | CHF 38.7B | CHF 147.1B | CHF 33.39 | 2.69% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | CHF 37.4B | CHF 152.7B | CHF 88.15 | 0.13% down | 17% down | ||
| 12 | GSKGSK · Health Care | CHF 36.5B | CHF 82.4B | CHF 41.13 | 0.91% down | 6% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | CHF 23.8B | CHF 57.6B | CHF 18.03 | 1.16% down | 54% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | CHF 14.5B | CHF 41.5B | CHF 35.61 | 0.89% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | CHF 12.1B | CHF 82.8B | CHF 800.14 | 0.89% down | 36% up | ||
| 16 | ViatrisVTRS · Health Care | CHF 12.1B | CHF 20B | CHF 17.48 | 1.39% up | 96% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | CHF 10.1B | CHF 114.5B | CHF 451.76 | 0.33% up | 27% up | ||
| 18 | ZoetisZTS · Health Care | CHF 8B | CHF 29B | CHF 71.49 | 1.60% up | 29% down | ||
| 19 | GrifolsGRFS · Health Care | CHF 7B | CHF 4.9B | CHF 7.14 | 1.91% down | 1% up | ||
| 20 | BeOne MedicinesONC · Health Care | CHF 4.5B | CHF 39B | CHF 341.86 | 1.86% down | 17% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | CHF 4B | CHF 11.3B | CHF 22.60 | 3.71% up | 20% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | CHF 3.6B | CHF 13.3B | CHF 207.73 | 2.38% up | 37% up | ||
| 23 | GenmabGMAB · Health Care | CHF 3.1B | CHF 26.8B | CHF 43.41 | 0.89% down | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | CHF 3.1B | CHF 17.2B | CHF 128.23 | 2.80% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | CHF 3B | CHF 10.6B | CHF 12.66 | 1.52% up | 5% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | CHF 2.7B | CHF 9.9B | CHF 51.11 | 3.63% up | 11% up | ||
| 27 | United TherapeuticsUTHR · Health Care | CHF 2.7B | CHF 20.9B | CHF 489.75 | 0.53% down | 23% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | CHF 2.5B | CHF 6.4B | CHF 18.51 | 3.98% up | 83% up | ||
| 29 | Royalty PharmaRPRX · Health Care | CHF 2B | CHF 33.6B | CHF 58.42 | 0.90% up | 78% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | CHF 1.5B | CHF 4.3B | CHF 50.97 | 0.18% up | 20% down | ||
| 31 | AlkermesALKS · Health Care | CHF 1.2B | CHF 6.6B | CHF 39.47 | 3.01% up | 58% up | ||
| 32 | Legend BiotechLEGN · Health Care | CHF 867.3M | CHF 2.7B | CHF 13.66 | 0.62% up | 42% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | CHF 807.9M | CHF 8B | CHF 342.71 | 3.65% down | 24% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | CHF 795.5M | CHF 3.9B | CHF 23.26 | 2.34% up | 64% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | CHF 699.2M | CHF 5.2B | CHF 36.69 | 1.24% up | 10% up | ||
| 36 | Ascendis PharmaASND · Health Care | CHF 673.5M | CHF 15B | CHF 228.91 | 0.14% up | 28% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | CHF 641.8M | CHF 6.3B | CHF 57.62 | 2.45% down | 8% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | CHF 571.1M | CHF 6.3B | CHF 80.52 | 0.44% up | 126% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | CHF 538.2M | CHF 5.9B | CHF 112.71 | 1.64% down | 7% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | CHF 519.5M | CHF 8.4B | CHF 55.82 | 5.61% up | 107% up | ||
| 41 | InsmedINSM · Health Care | CHF 511.2M | CHF 22.4B | CHF 101.96 | 0.74% down | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | CHF 439.4M | CHF 5.1B | CHF 77.63 | 0.15% up | 31% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | CHF 423.2M | CHF 12.8B | CHF 65.68 | 1.46% up | 17% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | CHF 413.6M | CHF 4.1B | CHF 43.18 | 0.25% up | 44% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | CHF 226M | CHF 5.1B | CHF 253.48 | 2.35% up | 43% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | CHF 160M | CHF 7B | CHF 100.39 | 2.14% up | 13% up | ||
| 47 | CytokineticsCYTK · Health Care | CHF 74.2M | CHF 6.1B | CHF 43.53 | 0.01% down | 20% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | CHF 38.8M | CHF 6.9B | CHF 105.72 | 0.60% up | 46% up | ||
| 49 | Roivant SciencesROIV · Health Care | CHF 7M | CHF 23.6B | CHF 32.59 | 0.12% down | 90% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | CHF 1.7M | CHF 4.1B | CHF 73.55 | 0.31% up | 113% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | CHF 0 | CHF 7.8B | CHF 82.11 | 3.84% up | 286% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | CHF 0 | CHF 7.3B | CHF 260.09 | 1.15% up | 61% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8429 CHF). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by revenue?
Johnson & Johnson (CHF 79.4B), Eli Lilly (CHF 54.9B) and Merck & Co (CHF 54.8B) are the top three of the 52 pharmaceutical companies ranked by revenue as of 18 Nov 2026, 17:48 UTC.
How many pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 52 pharmaceutical companies ranked by revenue have a combined market value of CHF 4.29T as of 18 Nov 2026, 17:48 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.